gadolinium has been researched along with Multiple Sclerosis, Relapsing-Remitting in 132 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.76) | 18.2507 |
| 2000's | 52 (39.39) | 29.6817 |
| 2010's | 60 (45.45) | 24.3611 |
| 2020's | 19 (14.39) | 2.80 |
| Authors | Studies |
|---|---|
| Culpepper, W; Jin, S; Lee-Wilk, T; Leekoff, M; Wallin, M | 1 |
| Arnold, DL; Collins, DL; Dadar, M; Mahmoud, S; Maranzano, J; Narayanan, S | 1 |
| Dincic, E; Georgievski-Brkic, B; Jovanovski, A; Koprivsek, K; Kostic, D; Kostic, S; Misovic, M; Rancic, N | 1 |
| Lin, M; Luo, J; Shi, S; Zhang, J; Zhang, Y | 1 |
| Adlard, N; Brennan, R; Cameron, C; Drudge, C; Giovannoni, G; Haltner, A; Häring, DA; Klotz, L; Samjoo, IA; Worthington, E; Zhao, M | 1 |
| Bisecco, A; Capuano, R; d'Ambrosio, A; Di Filippo, M; Fiacca, A; Gaetani, L; Gallo, A; Gentili, L; Guercini, G; Mancini, A; Parnetti, L; Tedeschi, G | 1 |
| Alvarez, E; Bosco, JA; Cree, BAC; Cutter, G; Fox, E; Hartung, HP; Hsu, Y; Huang, D; Lee, L; Miskin, HP; Mok, K; Power, SA; Qian, P; Robertson, D; Selmaj, K; Steinman, L; Weiss, MS; Wray, S; Wynn, D; Xu, Y | 1 |
| Christine, LF; Grouin, JM; Kobelt, G; Labauge, P; Laplaud, D; Lotz, M; Manchon, E; Moreau, T; Pau, D; Vukusic, S | 1 |
| Abbadessa, G; Avolio, C; Barone, S; Bonavita, S; Callari, G; Cellerino, M; D'Amico, E; Ferraro, D; Granella, F; Inglese, M; Lus, G; Messina, C; Patti, F; Signoriello, E; Sola, P; Tsantes, E; Valentino, P; Zanghì, A | 1 |
| Affinito, G; Brescia Morra, V; Caliendo, D; Carotenuto, A; Dallera, G; Moccia, M; Palladino, R; Petracca, M; Triassi, M | 1 |
| Hemmer, B; Höfler, J; Hornuss, C; Liedert, B; Roth, K; Selmaj, K; Wessels, H; Wiendl, H | 1 |
| Deiva, K; Maillart, E; Maurey, H; Saponaro, AC; Tully, T | 1 |
| Ahmed, SF; Al-Hashel, J; AlMojel, M; Alroughani, R | 1 |
| Barkhof, F; Heijst, JA; Killestein, J; Moraal, B; Noteboom, S; Schoonheim, MM; Strijbis, EM; Teunissen, CE; Uitdehaag, BM; Van Kempen, ZL; Van Lierop, ZY; Wessels, MH | 1 |
| Altieri, M; Bernitsas, E; Brenner, MJ; Di Stadio, A; Dipietro, L; Kaski, D; Messineo, D; Ralli, M | 1 |
| Aouinti, S; Ayrignac, X; Bigaut, K; Carra Dallière, C; Charif, M; Collongues, N; de Seze, J; Demortiere, S; Kremer, L; Labauge, P; Maarouf, A; Pelletier, J; Picot, MC; Pinna, F | 1 |
| Capra, R; Galgani, S; Gasperini, C; Haggiag, S; Montalban, X; Pozzilli, C; Prosperini, L; Río, J; Rovira, À; Sastre-Garriga, J; Tintoré, M; Tortorella, C | 1 |
| Brisset, JC; Cotton, F; Vukusic, S | 1 |
| Allen, CM; Chataway, J; Evangelou, N; Fernandes, L; Ford, HL; Tallantyre, E; Williams, T | 1 |
| Budhram, A; Kremenchutzky, M; Pelikan, JB; Sharma, M | 1 |
| Alcala-Vicente, C; Bosca-Blasco, I; Casanova-Estruch, B; Coret-Ferrer, F; Gascon-Gimenez, F; Navarre-Gimeno, A; Perez-Miralles, FC | 1 |
| Arnold, DL; Castrillo-Viguera, C; You, X | 1 |
| Alonso, A; Eisele, P; Gass, A; Ong, M; Platten, M; Schoenberg, SO; Szabo, K | 1 |
| Coyle, PK; Dangond, F; Fang, J; Freedman, MS; Reder, AT | 1 |
| Arnold, DL; Cadavid, D; Cook, S; Maranzano, J; Nakamura, K; Narayanan, S; Rudko, DA; Wolansky, L | 1 |
| Buttari, F; Centonze, D; Di Iorio, G; Landi, D; Lus, G; Marfia, GA; Monteleone, F; Nicoletti, CG; Saccà, F; Sica, F; Signoriello, E | 1 |
| Barrell, K; Chataway, J; Martin, K; Sharrack, B; Stolt, P; Wraith, DC | 1 |
| Aboulwafa, M; Clarelli, F; Comi, G; Dalla Costa, G; Esposito, F; Ferre', L; Filippi, M; Martinelli Boneschi, F; Martinelli, V; Mascia, E; Moiola, L; Radaelli, M; Rocca, MA; Sangalli, F; Sferruzza, G | 1 |
| Arru, M; Barracciu, MA; Cocco, E; Coghe, G; Fenu, G; Frau, J; Fronza, M; Loi, L; Lorefice, L; Marrosu, MG | 1 |
| Boffa, L; Buscarinu, MC; Centonze, D; Cortese, A; Di Battista, G; Fantozzi, R; Ferraro, E; Francia, A; Gasperini, C; Haggiag, S; Landi, D; Marfia, GA; Mataluni, G; Millefiorini, E; Mirabella, M; Monteleone, F; Nociti, V; Pontecorvo, S; Pozzilli, C; Prosperini, L; Ragonese, P; Salemi, G; Salvetti, M | 1 |
| Adiutori, R; Altmann, D; Bianchi, L; Christensen, T; Giovannoni, G; Gold, J; Holden, D; MacManus, D; Marta, M; Meier, UC; Miller, D; Schmierer, K; Turner, B; Yousry, T | 1 |
| Arnold, DL; Barkhof, F; Belachew, S; Bernasconi, C; Elliott, C; Hauser, SL; Kappos, L; Wei, W; Wolinsky, JS | 1 |
| Kondo, T; Li, J; Mahadavan, L; Saida, T; Sheikh, SI; Yamamura, T; Yang, M; Yun, J; Zhu, B | 1 |
| Brescia Morra, V; Brunetti, A; Cocozza, S; Criscuolo, C; Di Stasi, M; Elefante, A; Lamberti, A; Lanzillo, R; Moccia, M; Monti, S; Palma, G; Paolella, C; Petracca, M; Pontillo, G; Russo, C; Tedeschi, E; Vola, EA | 1 |
| Buffels, R; Cree, BAC; Fiore, D; Garren, H; Han, J; Hauser, SL; Kappos, L; Montalban, X; Papeix, C; Turner, B; Wolinsky, JS | 1 |
| da Rocha, AJ; do Amaral, LLF; Fragoso, DC; Littig, IA; Nunes, RH | 1 |
| Amaral, LLFD; Fragoso, DC; Rocha, AJD | 1 |
| Fisher, E; Reich, DS | 1 |
| Hernández Torres, E; Laule, C; Li, DK; MacKay, AL; Moore, GR; Rauscher, A; Traboulsee, A; Vavasour, IM; Wiggermann, V | 1 |
| Cotton, F; Gobbi, C; Guttmann, CR; Leppert, D; Meier, DS; Sintzel, M; Zecca, C | 1 |
| Bojanic, V; Cvetkovic, T; Ljubisavljevic, S; Pavlovic, D; Stojanov, D; Stojanovic, D; Stojanovic, I; Stokanovic, D; Vojinovic, S | 1 |
| Elkins, J; Giovannoni, G; Greenberg, S; Havrdova, E; Mehta, L; Radue, EW; Riester, K | 1 |
| Araújo, D; Arnold, DL; Giacomini, PS; Lapierre, Y; Leppert, IR; Narayanan, S; Pike, GB | 1 |
| Erminio, C; La Mantia, L; Marazzi, MR; Prone, V; Protti, A | 1 |
| Barkhof, F; Haller, S; Lalive, PH; Wattjes, MP | 1 |
| Arnold, DL; Calabresi, PA; Deykin, A; Hung, S; Kieseier, BC; Liu, S; Sheikh, SI; Sperling, B; You, X; Zhu, Y | 1 |
| Aguglia, U; Amato, MP; Carreras, E; Currò, D; Di Bartolomeo, P; Di Gioia, M; Donelli, A; Farge, D; Filippi, M; Gualandi, F; Iacopino, P; Lugaresi, A; Mancardi, GL; Massacesi, L; Merelli, E; Rambaldi, A; Roccatagliata, L; Rottoli, MR; Saccardi, R; Saiz, A; Sormani, MP; Vuolo, L | 1 |
| Absinta, M; Butman, JA; Calabresi, PA; Cortese, IC; Fenton, K; Maric, D; Nair, G; Ohayon, J; Pardo, CA; Rao, A; Reich, DS; Reyes-Mantilla, MI; Sati, P; Vuolo, L | 1 |
| Louapre, C; Mainero, C | 1 |
| Bowen, JD; Carpenter, A; Corboy, JR; Fischkoff, SA; Freedman, MS; Hariri, RJ; Huddlestone, J; Kremenchutzky, M; Krupp, L; Lublin, FD; Paulo, C | 1 |
| Stojanov, DA | 1 |
| Chiang, GC; Comunale, JP; Gauthier, SA; Pinto, S | 1 |
| Faizy, T; Fiehler, J; Heesen, C; Holst, B; Sedlacik, J; Siemonsen, S; Stellmann, JP; Thaler, C; Young, KL | 1 |
| Elkins, J; Giovannoni, G; Gold, R; Havrdova, E; Radue, EW; Selmaj, K; Sprenger, T; Stefoski, D; Vollmer, T; You, X | 1 |
| Angelini, V; Borrelli, P; Brunetti, A; Canna, A; Cocozza, S; Lanzillo, R; Morra, VB; Palma, G; Postiglione, E; Quarantelli, M; Russo, C; Salvatore, M; Tedeschi, E | 1 |
| Deykin, A; Hang, Y; Hu, X; Liu, S; Nestorov, I; Zhang, J | 1 |
| Bergman, J; Birgander, R; de Flon, P; Dring, A; Gunnarsson, M; Krauss, W; Laurell, K; Lindqvist, T; Söderström, L; Sundström, P; Svenningsson, A | 1 |
| Arnold, DL; Byron, M; Ding, L; Freedman, MS; Gao, W; Khoury, SJ; Rochon, J; Ryker, K; Sayre, PH; Smilek, DE; Tosta, P | 1 |
| Arnold, DL; Brinar, VV; Cohen, JA; Coles, AJ; Compston, DA; Fisher, E; Giovannoni, G; Hartung, HP; Havrdova, E; Lake, SL; Margolin, DH; Panzara, MA; Selmaj, KW; Stojanovic, M; Thomas, DR; Weiner, HL | 1 |
| Bareno, J; Cabrera, L; Ortiz, P; Rovira, A; Rueda, K | 1 |
| Absinta, M; Cortese, IC; de Alwis, MP; Falini, A; Filippi, M; Jacobson, S; Martinelli, V; Meani, A; Nair, G; Nath, A; Ohayon, J; Reich, DS; Scotti, R; Smith, BR; Vuolo, L | 1 |
| Cutter, GR; Fleming, TR; Held, U; Hughes, MD; McFarland, HF; Miller, DH; Petkau, J; Reingold, SC; Wolinsky, JS | 1 |
| Arnold, DL; Bar-Or, A; Campagnolo, D; Dunn, J; Freedman, MS; Gazda, SK; Panitch, H; Vollmer, T | 1 |
| Daumer, M; Ebers, GC; Hintzen, R; Morrissey, S; Neuhaus, A | 1 |
| Bakshi, R; Guttmann, CR; Hayden, DL; Healy, BC; Sampat, MP | 1 |
| Diener, HC; Igwe, E; Kollia, K; Limmroth, V; Putzki, N; Woods, S | 1 |
| Bates, D; Galetta, S; Giovannoni, G; Havrdova, E; Hutchinson, M; Hyde, R; Kim, R; Lublin, FD; O'Connor, PW; Pace, A; Phillips, JT; Polman, CH; Stefoski, D | 1 |
| Koch-Henriksen, N | 1 |
| Arnold, DL; Francis, SJ; Giacomini, PS; Levesque, IR; Narayanan, S; Pike, GB; Ribeiro, L | 1 |
| Bester, M; Gerloff, C; Heesen, C; Leypoldt, F; Moeller, F; Münchau, A | 1 |
| Calabresi, PA; Confavreux, C; Galetta, SL; Giovannoni, G; Havrdova, E; Hutchinson, M; Kappos, L; Lublin, FD; Lynn, F; Miller, DH; O'Connor, PW; Panzara, MA; Phillips, JT; Polman, CH; Radue, EW; Rudick, RA; Stuart, WH; Wajgt, A; Weinstock-Guttman, B; Wynn, DR | 1 |
| Arora, A; Bakshi, R; Buckle, GJ; Duan, Y; Egorova, S; Gauthier, SA; Glanz, BI; Guttmann, CR; Khoury, SJ; Liptak, Z; Mandel, M; Neema, M; Stankiewicz, J; Tsagkaropoulos, A; Weiner, HL | 1 |
| Diener, HC; Putzki, N; Tettenborn, B; Yaldizli, O | 1 |
| Bonzano, L; Mancardi, GL; Roccatagliata, L; Sormani, MP | 1 |
| Cursiefen, S; Klawe, C; Kuckert, S; Limmroth, V; Maschke, M; Mäurer, M; Putzki, N; Tettenborn, B; Yaldizli, O | 1 |
| Constantin, M; Duquette, P; Godin, J; Li, D; Metz, LM; Myles, ML; Traboulsee, A; Yong, VW | 1 |
| Hourany, R; Itani, S; Sibaii, AM; Yaghi, S; Yamout, B | 1 |
| Aktas, O; Bellmann-Strobl, J; Dörr, J; Paul, F; Wernecke, KD; Wuerfel, J; Zipp, F | 1 |
| Algin, O; Hakyemez, B; Parlak, M; Taşkapilioğlu, O; Turan, F | 1 |
| Enzevaei, A; Firouznia, K; Ghanaati, H; Harirchian, MH; Jannati, A; Karvigh, SA; Moghadam, NB; Nabavi, M; Nourian, A; Sahraian, MA; Shekiba, M; Togha, M | 1 |
| Cross, AH; Lauber, J; Lyons, JA; Naismith, RT; Parks, BJ; Piccio, L; Song, SK; Trinkaus, K; Tutlam, NT | 1 |
| Cutter, G; Datta, S; Juneja, V; Narayana, PA; Nelson, F; Poonawalla, AH; Wolinsky, JS | 1 |
| Comi, G; Edan, G; Filippi, M; Le Page, E; Leray, E; Rocca, MA | 1 |
| Dawson, K; Dufek, M; Eraksoy, M; Gold, R; Havrdova, E; Kappos, L; Limmroth, V; MacManus, DG; Meluzinova, E; Miller, DH; O'Neill, GN; Polman, CH; Schmierer, K; Yang, M; Yousry, TA | 1 |
| Blevins, G; De Stefano, N; Drulovic, JS; Gasperini, C; Issard, D; Shotekov, P; Sormani, MP; Stubinski, B | 1 |
| Arnason, B; Beckmann, K; Bogumil, T; Comi, G; Cook, S; Filippi, M; Goodin, DS; Hartung, HP; Jeffery, D; Kappos, L; Knappertz, V; O'Connor, P; Petkau, J; Pohl, C; Sandbrink, R; White, R | 1 |
| Bar-Or, A; Barkhof, F; Calabresi, PA; Glanzman, R; Hauser, SL; Kappos, L; Leppert, D; Li, D; O'Connor, P; Tinbergen, J; Yin, M | 1 |
| Brum, DG; Comini-Frota, ER; Donadi, EA; Kaimen-Maciel, DR; Miranda, EC; Rodrigues, DH; Teixeira, AL | 1 |
| Atkinson, G; Dua, P; Graff, O; Grove, R; Horrigan, J; Macmanus, D; Miller, DH; Montalban, X; Wardell, C; Weber, T; Yousry, T | 1 |
| Hao, Q; Itoyama, Y; Kira, J; Saida, T; Tashiro, K | 1 |
| Buttmann, M; Hupp, M; Kerstan, A; Weise, G | 1 |
| Jakab, G | 1 |
| Bergsland, N; Carl, E; Durfee, J; Dwyer, MG; Hojnacki, D; Hussein, S; Kennedy, C; Weinstock-Guttman, B; Zivadinov, R | 1 |
| Bakke, SJ; Beiske, AG; Benth, JŠ; Bjerve, KS; Bjørnarå, BT; Holmøy, T; Hovdal, H; Lilleås, F; Løken-Amsrud, KI; Midgard, R; Myhr, KM; Pedersen, T; Torkildsen, Ø; Wergeland, S | 1 |
| Barker, GJ; Chard, DT; Dehmeshki, J; Griffin, CM; Miller, DH; Parker, GJ; Thompson, AJ | 1 |
| Capello, E; Codella, M; Comi, G; Filippi, M; Ghezzi, A; Mancardi, G; Moiola, L; Rovaris, M; Sardanelli, F; Zaffaroni, M | 1 |
| Clanet, M; Hartung, HP; Hohlfeld, R; Kappos, L; Kooijmans-Coutinho, MF; Radue, EW; Sandberg-Wollheim, M; Sandrock, AW; Tsao, EC | 1 |
| Fazekas, F; Hartung, HP; Kieseier, BC; Quehenberger, F; Ropele, S; Seifert, T; Strasser-Fuchs, S | 1 |
| Enzinger, C; Fazekas, F; Ropele, S; Seifert, T; Strasser-Fuchs, S | 1 |
| Blumhardt, LD; Dalton, CM; Khan, OA; Libonati, MA; Miller, DH; Miszkiel, KA; O'Connor, PW; Rice, GP; Sheremata, WA; Willmer-Hulme, AJ | 1 |
| Barkhof, F; Eikelenboom, MJ; Giovannoni, G; Lazeron, RH; Petzold, A; Polman, CH; Sharief, M; Silber, E; Thompson, EJ; Uitdehaag, BM | 1 |
| Losy, J; Niezgoda, A; Zaremba, J | 1 |
| Castellà, MD; Montalban, X; Pericot, I; Río, J; Rovira, A; Tintoré, M | 1 |
| Baricordi, OR; Castellazzi, M; Fainardi, E; Govoni, V; Granieri, E; Marzola, A; Melchiorri, L; Paolino, E; Rizzo, R; Tola, MR; Vaghi, L | 1 |
| Clanet, M; Fisher, E; Freitag, P; Hardmeier, M; Kappos, L; Kooijmans-Coutinho, M; Radue, EW; Rudick, RA; Wagenpfeil, S | 1 |
| Barker, GJ; Dalton, CM; Hulme, A; MacManus, DG; Miller, DH; Miszkiel, KA; O'Connor, P; Panzara, M; Pepple, TI; Yang, M | 1 |
| Antel, JP; Bell, RB; Duquette, P; Metz, LM; Mitchell, JR; Patry, DG; Patten, SB; Stoian, CA; Yeung, M; Yong, VW; Zhang, Y | 1 |
| Corboy, J; Durkalski, V; Key, L; Markovic-Plese, S; Preiningerova, J; Rizzo, M; Singh, I; Tyor, W; Vollmer, T | 1 |
| Goodman, A; Libonati, MA; Metz, L; Murray, RS; O'Connor, PW; Sheremata, WA; Stone, LA; Vollmer, TL; Willmer-Hulme, AJ | 1 |
| Bagnato, F; Bakshi, R; Bastianello, S; Bratina, A; Catalan, M; Clemenzi, A; Dwyer, M; Finamore, L; Grop, A; Locatelli, L; Millefiorini, E; Nasuelli, D; Watts, K; Zivadinov, R; Zorzon, M | 1 |
| Fisher, E; Lee, JC; Ransohoff, RM; Rudick, RA; Simon, J | 1 |
| Braga, FT; da Rocha, AJ; da Silva, CJ; Maia, AC; Mendes, MF; Tilbery, CP | 1 |
| Burdette, J; Chepuri, N; Durden, D; Jeffery, DR | 1 |
| Amaducci, L; Barilaro, A; Konze, A; Massacesi, L; Parigi, A; Pellicanò, G; Repice, AM; Siracusa, G; Taiuti, R | 1 |
| Auer, DP; Blazevic, M; Daumer, M; Held, U; Holsboer, F; Kümpfel, T; Schumann, E; Schwan, M; Then Bergh, F; Trenkwalder, C; Uhr, M; Weber, F; Wismüller, A; Yassouridis, A | 1 |
| Airas, L; Elovaara, I; Mikkola, J; Smith, DJ; Vainio, JM | 1 |
| Antel, J; Comi, G; Haas, T; Kappos, L; Karlsson, G; Korn, AA; Montalban, X; O'Connor, P; Polman, CH; Radue, EW | 1 |
| Altmann, DR; Chard, DT; Davies, GR; Griffin, CM; Miller, DH; Rashid, W; Thompson, AJ | 1 |
| Barker, GJ; Fernando, KT; Fisher, E; Giovannoni, G; Havrdova, E; Hutchinson, M; Kappos, L; Lublin, FD; Lynn, F; MacManus, DG; Miller, DH; O'Connor, PW; Panzara, MA; Phillips, JT; Polman, CH; Rudick, R; Sandrock, AW; Soon, D; Wajgt, A; Yousry, TA | 1 |
| Li, D; Petkau, AJ; Traboulsee, A; Zhao, Y | 1 |
| Alexander, JS; Gonzalez-Toledo, E; Jimenez, JJ; Jy, W; Kelley, RE; Mauro, L; Minagar, A; Schwendimann, RN; Smith, SJ | 1 |
| Bensa, C; Brassat, D; Brochet, B; Clavelou, P; De Seze, J; Debouverie, M; Labauge, P; Lebrun, C; Roullet, E; Wiertlievski, S | 1 |
| Agarwal, S; Antel, J; Arnold, DL; Bar-Or, A; Fox, RJ; Hauser, SL; Langer-Gould, A; Panzara, M; Sarkar, N; Smith, CH; Vollmer, T; Waubant, E | 1 |
| Aktas, O; Bellmann-Strobl, J; Dörr, J; Haertle, M; Paul, F; Volk, HD; Waiczies, H; Waiczies, S; Wernecke, KD; Wuerfel, J; Zipp, F | 1 |
| Bastianello, S; Ciccarelli, O; Gasperini, C; Giugni, E; Mainero, C; Paolillo, A; Pozzilli, C | 1 |
| Bagnato, F; Bash, C; Bastianello, S; Frank, JA; Gasperini, C; McFarland, H; Pozzilli, C; Richert, N; Tancredi, A | 1 |
| Dastidar, P; Elovaara, I; Lehtimäki, T; Leppäkynnäs, M; Luomala, M; Peltola, J; Ukkonen, M | 1 |
| Avolio, C; Defazio, G; Giorelli, M; Giuliani, F; Livrea, P; Paolicelli, D; Trojano, M | 1 |
| Babb, JS; Ge, Y; Grossman, RI; Mannon, LJ; Saindane, AM; Udupa, JK | 1 |
| Bacchetti, P; Goodkin, DE; Luks, TL; Majumdar, S; Nelson, SJ; Portnoy, D; Sloan, R | 1 |
| Milicic, B; Samardzic, G; Toncev, G; Toncev, S | 1 |
| Bagnato, F; Bastianello, S; Galgani, S; Gasperini, C; Giugni, E; Mainero, C; Onesti, E; Paolillo, A; Pozzilli, C | 1 |
4 review(s) available for gadolinium and Multiple Sclerosis, Relapsing-Remitting
| Article | Year |
|---|---|
Ocrelizumab for multiple sclerosis.
Topics: Adult; Antibodies, Monoclonal, Humanized; Gadolinium; Humans; Interferon beta-1a; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2022 |
Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Topics: Adult; Gadolinium; Humans; Immunologic Factors; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Patient Reported Outcome Measures; Quality of Life; Recurrence | 2022 |
Update on brain MRI for the diagnosis and follow-up of MS patients.
Topics: Brain; Contrast Media; Follow-Up Studies; Gadolinium; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Practice Guidelines as Topic; Registries; Treatment Outcome | 2021 |
Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?
Topics: Drug Monitoring; Gadolinium; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic; Regression Analysis | 2009 |
56 trial(s) available for gadolinium and Multiple Sclerosis, Relapsing-Remitting
| Article | Year |
|---|---|
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Crotonates; Double-Blind Method; Gadolinium; Humans; Hydroxybutyrates; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Toluidines | 2022 |
Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial.
Topics: Adult; Biosimilar Pharmaceuticals; Female; Gadolinium; Humans; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neoplasm Recurrence, Local; Recurrence; Treatment Outcome | 2023 |
Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study.
Topics: Adult; Contrast Media; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Gadolinium; Humans; Immunologic Factors; Interferon-beta; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Polyethylene Glycols; Time-to-Treatment; Treatment Outcome | 2017 |
Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon β-1a in the EVIDENCE study.
Topics: Adolescent; Adult; Brain; Drug Administration Schedule; Female; Gadolinium; Humans; Injections, Intramuscular; Injections, Subcutaneous; Interferon beta-1a; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neuroimaging; Treatment Outcome; Young Adult | 2017 |
MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis.
Topics: Acute Disease; Adolescent; Adult; Blood-Brain Barrier; Cerebral Cortex; Female; Gadolinium; Humans; Image Enhancement; Inflammation; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; White Matter; Young Adult | 2017 |
Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis.
Topics: Adult; Contrast Media; Dose-Response Relationship, Drug; Female; Gadolinium; Humans; Immunologic Factors; Immunotherapy; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Myelin Basic Protein; Peptide Fragments; Treatment Outcome | 2018 |
A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study.
Topics: Adult; Contrast Media; Disease Progression; Female; Gadolinium; HIV Integrase Inhibitors; Humans; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Raltegravir Potassium; Treatment Failure | 2018 |
A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries.
Topics: Adult; Asia, Eastern; Czech Republic; Delayed-Action Preparations; Dimethyl Fumarate; Double-Blind Method; Female; Gadolinium; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Poland; Treatment Outcome | 2019 |
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Disability Evaluation; Double-Blind Method; Drug Administration Routes; Female; Gadolinium; Humans; Image Processing, Computer-Assisted; Immunologic Factors; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Sex Factors; Young Adult | 2019 |
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.
Topics: Adult; Antibodies, Monoclonal, Humanized; Disability Evaluation; Double-Blind Method; Female; Follow-Up Studies; Gadolinium; Humans; Immunologic Factors; Interferon beta-1b; Interferon-beta; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Pilot Projects; Young Adult | 2013 |
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Contrast Media; Daclizumab; Disability Evaluation; Disease Progression; Female; Gadolinium; Humans; Image Processing, Computer-Assisted; Immunoglobulin G; Immunosuppressive Agents; Injections, Subcutaneous; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Secondary Prevention; Treatment Outcome; Young Adult | 2014 |
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Topics: Adult; Brain; Contrast Media; Disease Progression; Double-Blind Method; Female; Gadolinium; Humans; Immunologic Factors; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Polyethylene Glycols; Treatment Outcome | 2014 |
Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial.
Topics: Adult; Antineoplastic Agents; Female; Gadolinium; Hematopoietic Stem Cell Transplantation; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2015 |
Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
Topics: Adult; Brain; Canada; Contrast Media; Disability Evaluation; Double-Blind Method; Female; Follow-Up Studies; Gadolinium; Humans; Magnetic Resonance Imaging; Male; Mesenchymal Stem Cell Transplantation; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Severity of Illness Index; Treatment Outcome; United States | 2014 |
Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Topics: Adult; Antibodies, Monoclonal, Humanized; Daclizumab; Double-Blind Method; Female; Gadolinium; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care | 2016 |
Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients.
Topics: Adjuvants, Immunologic; Area Under Curve; Contrast Media; Drug Administration Schedule; Gadolinium; Half-Life; Humans; Image Enhancement; Injections, Subcutaneous; Interferon-beta; Magnetic Resonance Imaging; Models, Biological; Multiple Sclerosis, Relapsing-Remitting; Polyethylene Glycols; Recurrence; Treatment Outcome | 2016 |
Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.
Topics: Adult; Biomarkers; Contrast Media; Disability Evaluation; Drug Substitution; Female; Follow-Up Studies; Gadolinium; Glatiramer Acetate; Humans; Immunologic Factors; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neurofilament Proteins; Rituximab; Sweden; Treatment Outcome; Young Adult | 2016 |
ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis.
Topics: Abatacept; Adult; Double-Blind Method; Female; Gadolinium; Humans; Interferon-beta; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome | 2017 |
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Brain; Contrast Media; Female; Gadolinium; Humans; Immunologic Factors; Injections, Subcutaneous; Interferon beta-1a; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Organ Size; Treatment Outcome | 2016 |
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
Topics: Adult; Brain; Drug Therapy, Combination; Female; Gadolinium; Glatiramer Acetate; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Organ Size; Peptides; Regression Analysis; Single-Blind Method | 2008 |
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Disability Evaluation; Disease-Free Survival; Double-Blind Method; Female; Gadolinium; Humans; Immunosuppressive Agents; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Odds Ratio; Retrospective Studies; Young Adult | 2009 |
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Disease Progression; Female; Gadolinium; Humans; Immunologic Factors; Interferon beta-1a; Interferon-beta; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Proportional Hazards Models; Recurrence; Severity of Illness Index; Treatment Outcome; Young Adult | 2009 |
Multiple sclerosis associated fatigue during natalizumab treatment.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cohort Studies; Fatigue; Female; Gadolinium; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies; Recurrence; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2009 |
Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Central Nervous System; Contrast Media; Disability Evaluation; Drug Resistance; Female; Gadolinium; Germany; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Outcome Assessment, Health Care; Peptides; Retrospective Studies; Secondary Prevention; Severity of Illness Index; Treatment Failure; Young Adult | 2010 |
Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
Topics: Adjuvants, Immunologic; Adult; Anti-Bacterial Agents; Brain; Double-Blind Method; Drug Therapy, Combination; Female; Gadolinium; Glatiramer Acetate; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Minocycline; Multiple Sclerosis, Relapsing-Remitting; Peptides; Treatment Outcome; Young Adult | 2009 |
Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Topics: Adjuvants, Immunologic; Adult; Contrast Media; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Female; Gadolinium; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Interferon beta-1a; Interferon-beta; Iran; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Simvastatin; Treatment Outcome; Young Adult | 2010 |
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Disability Evaluation; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Gadolinium; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Rituximab; Severity of Illness Index; Time Factors; Young Adult | 2010 |
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.
Topics: Adult; Brain; Drug Administration Schedule; Drug Therapy, Combination; Female; Gadolinium; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon beta-1b; Interferon-beta; Magnetic Resonance Imaging; Male; Methylprednisolone; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Neuroimaging; Severity of Illness Index | 2011 |
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.
Topics: Adolescent; Adult; Brain; Contrast Media; Dimethyl Fumarate; Female; Fumarates; Gadolinium; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome; Young Adult | 2012 |
Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
Topics: Adjuvants, Immunologic; Albumins; Animals; Antibodies, Neutralizing; Atrophy; Cattle; Chemistry, Pharmaceutical; Gadolinium; Humans; Injections, Subcutaneous; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Secondary Prevention; Serum Albumin, Bovine; Treatment Outcome | 2012 |
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antibodies, Neutralizing; Cross-Sectional Studies; Disability Evaluation; Drug Resistance; Gadolinium; Humans; Interferon beta-1b; Interferon-beta; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Young Adult | 2012 |
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Topics: Adult; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Brain; Contrast Media; Double-Blind Method; Drug Administration Schedule; Female; Gadolinium; Humans; Infusions, Intravenous; Interferon-beta; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting | 2011 |
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antibodies, Monoclonal; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Gadolinium; Humans; Integrin alpha4beta1; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Placebos; Treatment Outcome | 2012 |
Intramuscular interferon beta-1a is effective in Japanese patients with relapsing-remitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhanced MRI brain lesions.
Topics: Adolescent; Adult; Asian People; Brain; Female; Gadolinium; Humans; Image Enhancement; Immunologic Factors; Injections, Intramuscular; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neopterin; Young Adult | 2012 |
Comparison of standard 1.5 T vs. 3 T optimized protocols in patients treated with glatiramer acetate. A serial MRI pilot study.
Topics: Adult; Brain; Female; Gadolinium; Glatiramer Acetate; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Peptides; Pilot Projects; Young Adult | 2012 |
Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses.
Topics: Adolescent; Adult; Gadolinium; Glatiramer Acetate; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Peptides; Treatment Outcome | 2002 |
A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.
Topics: Adolescent; Adult; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gadolinium; Humans; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Radionuclide Imaging; Random Allocation; Recurrence; Time Factors; Treatment Outcome | 2002 |
Quantitative magnetization transfer imaging of pre-lesional white-matter changes in multiple sclerosis.
Topics: Adjuvants, Immunologic; Adult; Female; Gadolinium; Humans; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Nerve Fibers | 2002 |
A controlled trial of natalizumab for relapsing multiple sclerosis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Brain; Double-Blind Method; Female; Gadolinium; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Statistics, Nonparametric | 2003 |
Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy.
Topics: Adult; Autoantibodies; Biomarkers; Brain; Brain Diseases; Disease Progression; Female; Gadolinium; Humans; Immunoglobulin G; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Neurofilament Proteins; Predictive Value of Tests | 2003 |
Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Chi-Square Distribution; Confidence Intervals; Double-Blind Method; Echo-Planar Imaging; Female; Follow-Up Studies; Gadolinium; Humans; Logistic Models; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Odds Ratio; Statistics, Nonparametric | 2004 |
Oral simvastatin treatment in relapsing-remitting multiple sclerosis.
Topics: Adjuvants, Immunologic; Administration, Oral; Adolescent; Adult; Brain; Contrast Media; Female; Gadolinium; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Simvastatin | 2004 |
Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.
Topics: Acute Disease; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Blood-Brain Barrier; Brain; Chemotaxis, Leukocyte; Contrast Media; Double-Blind Method; Female; Gadolinium; Humans; Integrin alpha4; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Severity of Illness Index; Treatment Outcome | 2004 |
Defining interferon beta response status in multiple sclerosis patients.
Topics: Adult; Brain Infarction; Disability Evaluation; Double-Blind Method; Female; Follow-Up Studies; Gadolinium; Humans; Image Enhancement; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Reproducibility of Results; Secondary Prevention; Severity of Illness Index; Time Factors; Treatment Outcome | 2004 |
A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Drug Therapy, Combination; Female; Gadolinium; Humans; Interferon beta-1b; Interferon-beta; Magnetic Resonance Imaging; Male; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Pilot Projects; Severity of Illness Index | 2005 |
Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
Topics: Adult; Azathioprine; Brain; Cross-Over Studies; Dose-Response Relationship, Drug; Encephalitis; Female; Gadolinium; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphocytes; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome | 2005 |
Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
Topics: Adult; Analysis of Variance; Anti-Inflammatory Agents; Brain; Cross-Over Studies; Dexamethasone; Drug Administration Schedule; Female; Gadolinium; Hormones; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Prolactin; Receptors, Cytokine; Time Factors; Treatment Outcome | 2006 |
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
Topics: Adolescent; Adult; Brain; Brain Diseases; Double-Blind Method; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Respiratory Tract Infections; Sphingosine; Statistics, Nonparametric | 2006 |
Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study.
Topics: Adult; Atrophy; Brain; Contrast Media; Disability Evaluation; Disease Progression; Early Diagnosis; Female; Gadolinium; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Sensitivity and Specificity | 2007 |
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Brain; Contrast Media; Double-Blind Method; Female; Follow-Up Studies; Gadolinium; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Organ Size; Treatment Outcome | 2007 |
Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Biomarkers; Brain; Cell Movement; Contrast Media; Doxycycline; Drug Therapy, Combination; Endothelium, Vascular; Female; Gadolinium; Humans; Injections, Intramuscular; Interferon beta-1a; Interferon-beta; Interferon-gamma; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Middle Aged; Monocytes; Multiple Sclerosis, Relapsing-Remitting; Multivariate Analysis; Neurologic Examination; Treatment Outcome; Tumor Necrosis Factor-alpha | 2008 |
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; B-Lymphocytes; Brain; Double-Blind Method; Female; Gadolinium; Humans; Immunoglobulins; Immunologic Factors; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Remission Induction; Rituximab | 2008 |
Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis.
Topics: Adjuvants, Immunologic; Administration, Oral; Atorvastatin; Gadolinium; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-beta; Interleukins; Magnetic Resonance Imaging; Models, Biological; Multiple Sclerosis, Relapsing-Remitting; Multivariate Analysis; Pyrroles; Recurrence; Treatment Outcome | 2008 |
Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis.
Topics: Adolescent; Adult; Female; Follow-Up Studies; Gadolinium; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting | 1999 |
Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy.
Topics: Adult; Atrophy; Brain; Cell Adhesion Molecules; E-Selectin; Enzyme-Linked Immunosorbent Assay; Female; Gadolinium; Humans; Immunohistochemistry; Inflammation; Injections, Intravenous; Integrin alpha4beta1; Integrins; Intercellular Adhesion Molecule-1; Lymphocyte Function-Associated Antigen-1; Lymphocytes; Magnetic Resonance Imaging; Male; Methylprednisolone Hemisuccinate; Middle Aged; Monocytes; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Predictive Value of Tests; Receptors, Lymphocyte Homing; Vascular Cell Adhesion Molecule-1 | 2000 |
Effects of rIFN-beta-1b on serum circulating ICAM-1 in relapsing remitting multiple sclerosis and on the membrane-bound ICAM-1 expression on brain microvascular endothelial cells.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Animals; Blood-Brain Barrier; Brain; Cells, Cultured; Endothelium, Vascular; Female; Gadolinium; Humans; Intercellular Adhesion Molecule-1; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Longitudinal Studies; Magnetic Resonance Imaging; Male; Microcirculation; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Rats; Solubility | 2000 |
72 other study(ies) available for gadolinium and Multiple Sclerosis, Relapsing-Remitting
| Article | Year |
|---|---|
Impact of comorbid post traumatic stress disorder on multiple sclerosis in military veterans: A population-based cohort study.
Topics: Cohort Studies; Disease Progression; Gadolinium; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Stress Disorders, Post-Traumatic; Veterans | 2022 |
Diffusely abnormal white matter converts to T2 lesion volume in the absence of MRI-detectable acute inflammation.
Topics: Brain; Contrast Media; Gadolinium; Humans; Inflammation; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; White Matter | 2022 |
Evolution of acute "black hole" lesions in patients with relapsing-remitting multiple sclerosis.
Topics: Adult; Brain; Contrast Media; Female; Gadolinium; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; White Matter | 2023 |
Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
Topics: Antibodies, Monoclonal, Humanized; Gadolinium; Humans; Immunologic Factors; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic | 2022 |
Impact of post-contrast MRI in the definition of active multiple sclerosis.
Topics: Brain; Gadolinium; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies | 2022 |
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic.
Topics: COVID-19; Gadolinium; Humans; Immunologic Factors; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pandemics; Recurrence | 2022 |
The independent contribution of brain, spinal cord and gadolinium MRI in treatment decision in multiple sclerosis: A population-based retrospective study.
Topics: Brain; Gadolinium; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Spinal Cord | 2023 |
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study.
Topics: Adolescent; Child; Follow-Up Studies; Gadolinium; Humans; Immunosuppressive Agents; Interferon beta-1a; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Retrospective Studies | 2023 |
A prospective observational longitudinal study with a two-year follow-up of multiple sclerosis patients on Cladribine.
Topics: Adult; Cladribine; Contrast Media; Female; Follow-Up Studies; Gadolinium; Humans; Immunosuppressive Agents; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies | 2023 |
Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
Topics: Biomarkers; Contrast Media; Disease Progression; Gadolinium; Glial Fibrillary Acidic Protein; Humans; Intermediate Filaments; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neurofilament Proteins; Neuroinflammatory Diseases | 2023 |
ENT-MS-12 questionnaire: A novel tool to investigate otolaryngology symptoms in patients with relapsing-remitting multiple sclerosis. Results from a pilot study.
Topics: Contrast Media; Disability Evaluation; Disease Progression; Gadolinium; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Otolaryngology; Pilot Projects; Surveys and Questionnaires | 2021 |
First line treatment failure: Predictive factors in a cohort of 863 Relapsing Remitting MS patients.
Topics: Adult; Cohort Studies; Contrast Media; Gadolinium; Humans; Multiple Sclerosis, Relapsing-Remitting; Treatment Failure | 2021 |
Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score.
Topics: Contrast Media; Disability Evaluation; Gadolinium; Glatiramer Acetate; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2021 |
The contemporary role of MRI in the monitoring and management of people with multiple sclerosis in the UK.
Topics: Contrast Media; Gadolinium; Humans; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; United Kingdom | 2021 |
The 'across the pons' sign: A possible novel radiographic finding in natalizumab-associated progressive multifocal leukoencephalopathy.
Topics: Adult; Brain; Contrast Media; Diagnosis, Differential; Female; Gadolinium; Humans; Immunologic Factors; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2017 |
[Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
Topics: Adult; Contrast Media; Disability Evaluation; Disease-Free Survival; Drug Substitution; Female; Fingolimod Hydrochloride; Follow-Up Studies; Gadolinium; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neuroimaging; Oligoclonal Bands; Prospective Studies; Treatment Outcome; Young Adult | 2017 |
Lack of T1 hyperintensity in the dentate nucleus after 15 administrations of a macrocyclic contrast agent in multiple sclerosis.
Topics: Adult; Cerebellar Nuclei; Contrast Media; Female; Gadolinium; Humans; Macrocyclic Compounds; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Organometallic Compounds; Retrospective Studies; Young Adult | 2018 |
Fingolimod reduces the clinical expression of active demyelinating lesions in MS.
Topics: Adult; Brain; Contrast Media; Disability Evaluation; Drug Substitution; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunologic Factors; Interferon beta-1a; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Spinal Cord; Treatment Outcome | 2018 |
Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod.
Topics: Adult; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Image Processing, Computer-Assisted; Immunosuppressive Agents; Longitudinal Studies; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Statistics, Nonparametric; Time Factors; Vitamin D | 2018 |
Does focal inflammation have an impact on cognition in multiple sclerosis? An MRI study.
Topics: Adult; Brain; Cognition; Contrast Media; Disability Evaluation; Female; Follow-Up Studies; Gadolinium; Humans; Linear Models; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Neuropsychological Tests | 2018 |
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis.
Topics: Abortion, Induced; Adult; Female; Gadolinium; Humans; Inflammation; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Neuroimaging; Recurrence; Retrospective Studies; Young Adult | 2018 |
Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
Topics: Adult; Brain; Contrast Media; Disease Progression; Female; Gadolinium; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; White Matter | 2019 |
MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis.
Topics: Adult; Aged; Contrast Media; Disability Evaluation; Disease Progression; Female; Gadolinium; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies | 2019 |
Gadolinium-Enhanced Susceptibility-Weighted Imaging in Multiple Sclerosis: Optimizing the Recognition of Active Plaques for Different MR Imaging Sequences.
Topics: Adolescent; Adult; Algorithms; Blood-Brain Barrier; Brain; Cohort Studies; Contrast Media; Female; Gadolinium; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neuroimaging; Retrospective Studies; Sensitivity and Specificity; Young Adult | 2019 |
Improving acute demyelinating lesion detection: which T1-weighted magnetic resonance acquisition is more sensitive to gadolinium enhancement?
Topics: Adolescent; Adult; Brain; Contrast Media; Demyelinating Diseases; Female; Gadolinium; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Sensitivity and Specificity; Young Adult | 2019 |
Imaging new lesions: enhancing our understanding of multiple sclerosis pathogenesis.
Topics: Brain; Contrast Media; Female; Gadolinium; Heterocyclic Compounds; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Organometallic Compounds | 2013 |
Magnetic resonance frequency shifts during acute MS lesion formation.
Topics: Adult; Brain; Contrast Media; Disease Progression; Female; Gadolinium; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting | 2013 |
Glutathione homeostasis disruption of erythrocytes, but not glutathione peroxidase activity change, is closely accompanied with neurological and radiological scoring of acute CNS inflammation.
Topics: Adolescent; Adult; Age Factors; Cross-Sectional Studies; Disability Evaluation; Encephalitis; Erythrocytes; Female; Gadolinium; Glutathione; Glutathione Peroxidase; Homeostasis; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Sex Factors; Young Adult | 2014 |
Interpreting therapeutic effect in multiple sclerosis via MRI contrast enhancing lesions: now you see them, now you don't.
Topics: Adolescent; Adult; Algorithms; Contrast Media; Female; Gadolinium; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Signal-To-Noise Ratio; Young Adult | 2014 |
Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.
Topics: Adult; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; Lymphopenia; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2014 |
Transient gadolinium leakage in natalizumab-treated multiple sclerosis.
Topics: Antibodies, Monoclonal, Humanized; Contrast Media; Extravasation of Diagnostic and Therapeutic Materials; Gadolinium; Humans; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2015 |
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.
Topics: Gadolinium; Humans; Magnetic Resonance Imaging; Meninges; Meningitis; Multiple Sclerosis, Relapsing-Remitting | 2015 |
Meningeal inflammation in multiple sclerosis: The key to the origin of cortical lesions?
Topics: Gadolinium; Humans; Magnetic Resonance Imaging; Meningitis; Multiple Sclerosis, Relapsing-Remitting | 2015 |
Reply to Letter to the Editor re: Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: Correlation with cumulative dose of a macrocy
Topics: Cerebellar Nuclei; Contrast Media; Gadolinium; Globus Pallidus; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2016 |
Gadolinium-Enhancing Lesions Lead to Decreases in White Matter Tract Fractional Anisotropy in Multiple Sclerosis.
Topics: Adult; Algorithms; Anisotropy; Brain; Corpus Callosum; Diffusion Tensor Imaging; Disease Progression; Female; Gadolinium; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nerve Fibers, Myelinated; Prospective Studies; Pyramidal Tracts; White Matter | 2016 |
T1- Thresholds in Black Holes Increase Clinical-Radiological Correlation in Multiple Sclerosis Patients.
Topics: Adolescent; Adult; Cerebral Cortex; Contrast Media; Disability Evaluation; Female; Gadolinium; Humans; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting | 2015 |
In vivo dentate nucleus MRI relaxometry correlates with previous administration of Gadolinium-based contrast agents.
Topics: Adult; Cerebellar Nuclei; Contrast Media; Female; Gadolinium; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies | 2016 |
[Magnetic resonance imaging with gadolinium in the acute phase of relapses in multiple sclerosis].
Topics: Adult; Contrast Media; Cross-Sectional Studies; Female; Gadolinium; Humans; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies | 2017 |
Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases.
Topics: Adult; Aged; Cohort Studies; Cross-Sectional Studies; Encephalitis; Female; Gadolinium; HIV Infections; Humans; Imaging, Three-Dimensional; Leukocyte Count; Linear Models; Magnetic Resonance Imaging; Male; Meninges; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nervous System Diseases; Oligoclonal Bands; Young Adult | 2017 |
Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses.
Topics: Biomarkers; Clinical Trials as Topic; Databases, Factual; Gadolinium; Humans; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Predictive Value of Tests; Prognosis; Recurrence; Treatment Outcome | 2008 |
MRI as an outcome in multiple sclerosis clinical trials.
Topics: Adult; Cross-Sectional Studies; Disability Evaluation; Gadolinium; Humans; Image Enhancement; Longitudinal Studies; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic | 2009 |
Unbiased treatment effect estimates by modeling the disease process of multiple sclerosis.
Topics: Brain; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computer Simulation; Gadolinium; Humans; Models, Biological; Models, Statistical; Multiple Sclerosis, Relapsing-Remitting; Normal Distribution; Poisson Distribution; Treatment Outcome | 2009 |
Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Brain; Disease Progression; Female; Gadolinium; Glatiramer Acetate; Humans; Immunologic Factors; Interferon-beta; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neuroprotective Agents; Peptides; Pilot Projects; Recurrence; Treatment Outcome | 2009 |
No shortcuts to outcome in MS clinical trials?
Topics: Gadolinium; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Measuring demyelination and remyelination in acute multiple sclerosis lesion voxels.
Topics: Acute Disease; Adult; Demyelinating Diseases; Female; Follow-Up Studies; Gadolinium; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Myelin Sheath | 2009 |
Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report.
Topics: Adult; Brain; Cerebral Hemorrhage; Contrast Media; Encephalitis; Epilepsy, Complex Partial; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Necrosis; Propylene Glycols; Sphingosine | 2009 |
Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study.
Topics: Adult; Contrast Media; Disease Progression; Female; Follow-Up Studies; Gadolinium; Glatiramer Acetate; Humans; Immunologic Factors; Incidence; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Peptides; Prospective Studies; Risk Factors; Treatment Failure; Young Adult | 2009 |
The effect of war stress on multiple sclerosis exacerbations and radiological disease activity.
Topics: Adult; Contrast Media; Female; Gadolinium; Humans; Interferons; Lebanon; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Radiography; Recurrence; Stress, Psychological; Warfare | 2010 |
Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis.
Topics: Adult; Analysis of Variance; Cognition Disorders; Contrast Media; Female; Gadolinium; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Neuropsychological Tests; Severity of Illness Index; Time Factors | 2009 |
Imaging of active multiple sclerosis plaques: efficiency of contrast-enhanced magnetization transfer subtraction technique.
Topics: Adult; Age of Onset; Brain; Contrast Media; Diagnostic Imaging; Disabled Persons; Female; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Sclerosis; Subtraction Technique; Young Adult | 2010 |
Composite MRI scores improve correlation with EDSS in multiple sclerosis.
Topics: Adult; Contrast Media; Cross-Sectional Studies; Disability Evaluation; Female; Gadolinium; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Predictive Value of Tests; Severity of Illness Index; Texas | 2010 |
Serum levels of brain-derived neurotrophic factor correlate with the number of T2 MRI lesions in multiple sclerosis.
Topics: Adult; Biomarkers; Brain-Derived Neurotrophic Factor; Case-Control Studies; Female; Gadolinium; Humans; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting | 2012 |
Lobular panniculitis and lipoatrophy of the thighs with interferon-ß1a for intramuscular injection in a patient with multiple sclerosis.
Topics: Adipose Tissue; Adult; Contrast Media; Drug Eruptions; Female; Gadolinium; Humans; Injections, Subcutaneous; Interferon beta-1a; Interferon-beta; Lipodystrophy; Magnetic Resonance Imaging; Medical Errors; Multiple Sclerosis, Relapsing-Remitting; Necrosis; Panniculitis; Skin; Thigh | 2012 |
[Assessment of the clinical and MRI results of the FREEDOMS and TRANSFORMS phase III. clinical trials].
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Congresses as Topic; Contrast Media; European Union; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Posters as Topic; Propylene Glycols; Secondary Prevention; Sphingosine; Time Factors; Treatment Failure; Treatment Outcome | 2012 |
Alpha-tocopherol and MRI outcomes in multiple sclerosis--association and prediction.
Topics: Adult; alpha-Tocopherol; Cohort Studies; Fatty Acids, Omega-3; Female; Follow-Up Studies; Gadolinium; HLA-DRB1 Chains; Humans; Interferon-beta; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
T1 histograms of normal-appearing brain tissue are abnormal in early relapsing-remitting multiple sclerosis.
Topics: Adult; Brain; Echo-Planar Imaging; Female; Gadolinium; Humans; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting | 2002 |
TACE mRNA expression in peripheral mononudear cells precedes new lesions on MRI in multiple sclerosis.
Topics: ADAM Proteins; ADAM17 Protein; Adult; Blood-Brain Barrier; Brain; Enzyme Induction; Female; Gadolinium; Gene Expression Regulation, Enzymologic; Humans; Leukocytes, Mononuclear; Longitudinal Studies; Magnetic Resonance Imaging; Male; Metalloendopeptidases; Multiple Sclerosis, Relapsing-Remitting; RNA, Messenger; Tumor Necrosis Factor-alpha | 2002 |
IL-15 is elevated in sera of patients with relapsing-remitting multiple sclerosis.
Topics: Adult; Female; Gadolinium; Humans; Interleukin-15; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Radiography | 2002 |
Serial gadolinium-enhanced MRI in acute attack of multiple sclerosis treated with plasma exchange.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Gadolinium; Humans; Magnetic Resonance Imaging; Male; Methylprednisolone; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Plasma Exchange | 2003 |
Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings.
Topics: Adult; Antibodies, Monoclonal; Blotting, Western; Enzyme-Linked Immunosorbent Assay; Female; Gadolinium; Histocompatibility Antigens Class I; HLA Antigens; HLA-G Antigens; Humans; Inflammation; Interleukin-10; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nervous System Diseases; Solubility | 2003 |
Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis.
Topics: Adult; Atrophy; Brain; Disability Evaluation; Follow-Up Studies; Gadolinium; Humans; Image Enhancement; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Time Factors | 2003 |
Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis.
Topics: Adult; Female; Gadolinium; Humans; Magnetic Resonance Imaging; Male; Minocycline; Multiple Sclerosis, Relapsing-Remitting | 2004 |
Short-term brain atrophy changes in relapsing-remitting multiple sclerosis.
Topics: Adult; Atrophy; Brain Diseases; Brain Mapping; Female; Gadolinium; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Predictive Value of Tests | 2004 |
Trigeminal involvement in multiple sclerosis: magnetic resonance imaging findings with clinical correlation in a series of patients.
Topics: Adult; Female; Gadolinium; Humans; Hypertrophy; Incidence; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Myelin Sheath; Pons; Trigeminal Nerve; Trigeminal Neuralgia | 2005 |
Elevated serum soluble vascular adhesion protein-1 (VAP-1) in patients with active relapsing remitting multiple sclerosis.
Topics: Adult; Aged; Amine Oxidase (Copper-Containing); Blood-Brain Barrier; Cell Adhesion; Cell Adhesion Molecules; Central Nervous System; Chemotaxis, Leukocyte; Endothelial Cells; Female; Gadolinium; Humans; Leukocytes; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Predictive Value of Tests; Up-Regulation | 2006 |
Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.
Topics: Adolescent; Adult; Confounding Factors, Epidemiologic; Control Groups; Cross-Over Studies; Data Interpretation, Statistical; Female; Gadolinium; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Placebo Effect; Placebos; Randomized Controlled Trials as Topic; Remission, Spontaneous; Treatment Outcome | 2008 |
Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile.
Topics: Adolescent; Adult; Brain; Cohort Studies; Contrast Media; Demyelinating Diseases; Early Diagnosis; Female; Follow-Up Studies; Gadolinium; Genetic Predisposition to Disease; Humans; Incidental Findings; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neurologic Examination; Optic Neuritis; Retrospective Studies; Risk Factors | 2008 |
Contrast-enhanced magnetic resonance activity in relapsing remitting multiple sclerosis patients: a short term natural history study.
Topics: Adult; Clinical Trials as Topic; Cohort Studies; Female; Gadolinium; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Poisson Distribution; Predictive Value of Tests | 2000 |
The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS.
Topics: Adult; Atrophy; Brain; Disease Progression; Female; Gadolinium; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Prognosis; Regression Analysis | 2000 |
A longitudinal study of ventricular volume in early relapsing-remitting multiple sclerosis.
Topics: Adolescent; Adult; Atrophy; Cerebral Ventricles; Cohort Studies; Gadolinium; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Regression Analysis | 2000 |
Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction.
Topics: Adolescent; Adult; Blood-Brain Barrier; Disability Evaluation; Female; Gadolinium; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Predictive Value of Tests; Severity of Illness Index; Uric Acid | 2002 |
MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Topics: Adolescent; Adult; Atrophy; Brain; Cohort Studies; Contrast Media; Disability Evaluation; Disease Progression; Female; Follow-Up Studies; Gadolinium; Humans; Immunologic Factors; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Severity of Illness Index | 2002 |